• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases.糖尿病、肥胖症和血脂异常对慢性肝病患者肝细胞癌风险的影响。
Clin Mol Hepatol. 2022 Oct;28(4):773-789. doi: 10.3350/cmh.2021.0383. Epub 2022 Aug 8.
2
Risk factors for non-alcoholic fatty liver disease are common in patients with non-B non-C hepatocellular carcinoma in India.在印度,非酒精性脂肪性肝病的危险因素在非B非C型肝细胞癌患者中很常见。
Indian J Gastroenterol. 2017 Sep;36(5):373-379. doi: 10.1007/s12664-017-0785-x. Epub 2017 Oct 4.
3
Non-alcoholic fatty liver disease is associated with greater risk of 30-day hospital readmission in the United States (U.S.).非酒精性脂肪性肝病与美国 30 天内再次住院的风险增加相关。
Ann Hepatol. 2023 Jul-Aug;28(4):101108. doi: 10.1016/j.aohep.2023.101108. Epub 2023 Apr 23.
4
Associations between type 2 diabetes mellitus and chronic liver diseases: evidence from a Mendelian randomization study in Europeans and East Asians.2 型糖尿病与慢性肝脏疾病的关联:来自欧洲人和东亚人群的孟德尔随机研究证据。
Front Endocrinol (Lausanne). 2024 Mar 1;15:1338465. doi: 10.3389/fendo.2024.1338465. eCollection 2024.
5
Diabetes mellitus, metabolic syndrome and obesity are not significant risk factors for hepatocellular carcinoma in an HBV- and HCV-endemic area of Southern Taiwan.在台湾南部乙型肝炎和丙型肝炎流行地区,糖尿病、代谢综合征和肥胖不是肝细胞癌的显著危险因素。
Kaohsiung J Med Sci. 2013 Aug;29(8):451-9. doi: 10.1016/j.kjms.2012.12.006. Epub 2013 Feb 9.
6
Association of metabolic traits with occurrence of nonalcoholic fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis of longitudinal cohort studies.代谢特征与非酒精性脂肪性肝病相关肝细胞癌发生的关系:纵向队列研究的系统评价和荟萃分析。
Saudi J Gastroenterol. 2022 Mar-Apr;28(2):92-100. doi: 10.4103/sjg.sjg_260_21.
7
Alcoholic liver disease confers a worse prognosis than HCV infection and non-alcoholic fatty liver disease among patients with cirrhosis: An observational study.一项观察性研究表明,在肝硬化患者中,酒精性肝病的预后比丙型肝炎病毒感染和非酒精性脂肪性肝病更差。
PLoS One. 2017 Oct 27;12(10):e0186715. doi: 10.1371/journal.pone.0186715. eCollection 2017.
8
Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.非酒精性脂肪性肝病、代谢风险因素与肝细胞癌:一个悬而未决的问题。
World J Gastroenterol. 2015 Apr 14;21(14):4103-10. doi: 10.3748/wjg.v21.i14.4103.
9
Increased prevalence but decreased survival of nonviral hepatocellular carcinoma compared to viral hepatocellular carcinoma in recent ten years.近十年来,非病毒性肝细胞癌的发病率增加,但生存率却低于病毒性肝细胞癌。
Sci Rep. 2024 Apr 20;14(1):9068. doi: 10.1038/s41598-024-59668-2.
10
The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma.肥胖和糖尿病对肝细胞癌风险的影响。
Ann Oncol. 2009 Feb;20(2):353-7. doi: 10.1093/annonc/mdn565. Epub 2008 Aug 22.

引用本文的文献

1
Gold/Prussian Blue-Based Nanocomposites with Dual Nanozyme Activities Exert a Synergistic Effect of Starvation Therapy and Sonodynamic Therapy in the Treatment of Liver Cancer.具有双纳米酶活性的金/普鲁士蓝基纳米复合材料在肝癌治疗中发挥饥饿疗法和超声动力学疗法的协同作用。
Int J Nanomedicine. 2025 Sep 1;20:10721-10737. doi: 10.2147/IJN.S490343. eCollection 2025.
2
[Overview of the prevalence and features of oncological diseases in type 2 diabetes and possible immunological mechanisms].[2型糖尿病中肿瘤性疾病的患病率、特征及可能的免疫机制概述]
Probl Endokrinol (Mosk). 2025 May 20;71(2):75-81. doi: 10.14341/probl13452.
3
The spatio-temporal trends and determinants of liver cancer attributable to specific etiologies: a systematic analysis from the Global Burden of Disease Study 2021.特定病因所致肝癌的时空趋势及决定因素:基于《2021年全球疾病负担研究》的系统分析
Glob Health Res Policy. 2025 May 20;10(1):22. doi: 10.1186/s41256-025-00416-y.
4
Modulation of glucose metabolism and insulin resistance following hepatitis C virus clearance via direct-acting antivirals.通过直接作用抗病毒药物清除丙型肝炎病毒后对葡萄糖代谢和胰岛素抵抗的调节
Sci Rep. 2025 Apr 26;15(1):14663. doi: 10.1038/s41598-025-97827-1.
5
Impact of Diabetes Mellitus and Obesity Comorbidities on Survival Outcomes after Hepatocellular Carcinoma Resection: A Multicenter Retrospective Study.糖尿病和肥胖合并症对肝细胞癌切除术后生存结局的影响:一项多中心回顾性研究
Liver Cancer. 2024 Aug 20;14(1):80-91. doi: 10.1159/000540858. eCollection 2025 Mar.
6
Advances and challenges in molecular understanding, early detection, and targeted treatment of liver cancer.肝癌分子认识、早期检测及靶向治疗的进展与挑战
World J Hepatol. 2025 Jan 27;17(1):102273. doi: 10.4254/wjh.v17.i1.102273.
7
Exploring How Adipose Tissue, Obesity, and Gender Influence the Immune Response to Vaccines: A Comprehensive Narrative Review.探索脂肪组织、肥胖和性别如何影响对疫苗的免疫反应:一项全面的叙述性综述。
Int J Mol Sci. 2025 Jan 20;26(2):862. doi: 10.3390/ijms26020862.
8
Impact of high body mass index on hepatocellular carcinoma risk in chronic liver disease: A population-based prospective cohort study.高体重指数对慢性肝病患者肝细胞癌风险的影响:一项基于人群的前瞻性队列研究。
PLoS One. 2025 Jan 22;20(1):e0316175. doi: 10.1371/journal.pone.0316175. eCollection 2025.
9
Prevention of liver cancer in the era of next-generation antivirals and obesity epidemic.下一代抗病毒药物与肥胖流行时代的肝癌预防
Hepatology. 2025 Jan 14. doi: 10.1097/HEP.0000000000001227.
10
Evolution of characteristics of MASLD with and without diabetes: a meta-analysis of placebo arms.伴或不伴糖尿病的 MASLD 特征演变:安慰剂对照臂的荟萃分析。
Sci Rep. 2024 Nov 22;14(1):28951. doi: 10.1038/s41598-024-79428-6.

本文引用的文献

1
Associations between diabetes mellitus and the risk of hepatocellular carcinoma in Asian individuals with hepatitis B and C infection: systematic review and a meta-analysis of cohort studies.乙型肝炎和丙型肝炎感染亚洲人群中糖尿病与肝细胞癌风险的相关性:系统评价和队列研究的荟萃分析。
Eur J Cancer Prev. 2022 Mar 1;31(2):107-116. doi: 10.1097/CEJ.0000000000000669.
2
Association of metabolic traits with occurrence of nonalcoholic fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis of longitudinal cohort studies.代谢特征与非酒精性脂肪性肝病相关肝细胞癌发生的关系:纵向队列研究的系统评价和荟萃分析。
Saudi J Gastroenterol. 2022 Mar-Apr;28(2):92-100. doi: 10.4103/sjg.sjg_260_21.
3
Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease.糖尿病药物和血糖控制对非酒精性脂肪性肝病患者肝细胞癌风险的影响。
Hepatology. 2022 Jun;75(6):1420-1428. doi: 10.1002/hep.32244. Epub 2021 Dec 19.
4
Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy.中心型肥胖与接受抗病毒治疗的慢性乙型肝炎患者肝细胞癌的相关性。
Aliment Pharmacol Ther. 2021 Aug;54(3):329-338. doi: 10.1111/apt.16469. Epub 2021 Jun 22.
5
Influence of Metabolic Syndrome on Cancer Risk in HBV Carriers: A Nationwide Population Based Study Using the National Health Insurance Service Database.代谢综合征对乙肝病毒携带者癌症风险的影响:一项基于全国健康保险服务数据库的全国性人群研究
J Clin Med. 2021 May 29;10(11):2401. doi: 10.3390/jcm10112401.
6
The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments.非酒精性脂肪性肝病与 2 型糖尿病之间的复杂关系——机制与治疗。
Nat Rev Gastroenterol Hepatol. 2021 Sep;18(9):599-612. doi: 10.1038/s41575-021-00448-y. Epub 2021 May 10.
7
Association between Lipid Profiles and the Incidence of Hepatocellular Carcinoma: A Nationwide Population-Based Study.血脂谱与肝细胞癌发病率之间的关联:一项基于全国人口的研究。
Cancers (Basel). 2021 Mar 30;13(7):1599. doi: 10.3390/cancers13071599.
8
Efficacy and Safety of Statin for Hepatocellular Carcinoma Prevention Among Chronic Liver Disease Patients: A Systematic Review and Meta-analysis.他汀类药物预防慢性肝病患者肝细胞癌的疗效和安全性:系统评价和荟萃分析。
J Clin Gastroenterol. 2021 Aug 1;55(7):615-623. doi: 10.1097/MCG.0000000000001478.
9
Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis.慢性乙型肝炎病毒 (HBV) 感染患者发生肝细胞癌 (HCC) 的危险因素:系统评价和荟萃分析。
J Viral Hepat. 2021 Mar;28(3):493-507. doi: 10.1111/jvh.13452. Epub 2020 Dec 28.
10
Correlation of Fasting Lipid Profile in Patients With Chronic Liver Disease: A Descriptive Cross-Sectional Study in Tertiary Care Hospital.慢性肝病患者空腹血脂谱的相关性:一项在三级医疗医院进行的描述性横断面研究。
Cureus. 2020 Oct 18;12(10):e11019. doi: 10.7759/cureus.11019.

糖尿病、肥胖症和血脂异常对慢性肝病患者肝细胞癌风险的影响。

Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases.

机构信息

Department of Family Medicine, Soonchunhyang University Hospital Cheonan, Soonchunhyang University College of Medicine, Cheonan, Korea.

Department of Internal Medicine, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea.

出版信息

Clin Mol Hepatol. 2022 Oct;28(4):773-789. doi: 10.3350/cmh.2021.0383. Epub 2022 Aug 8.

DOI:10.3350/cmh.2021.0383
PMID:35934813
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9597232/
Abstract

Despite the increasing prevalence of metabolic disorders, the potential effects of metabolic factors on hepatocellular carcinoma (HCC) development in individuals with chronic liver diseases (CLDs) are not well understood. For a metabolic factor to be identified as a risk factor for HCC in patients with CLDs, such as hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, there should be a strong synergistic interaction between the carcinogenic mechanisms of the metabolic factor and the CLD itself. This review aims to comprehensively summarize the published data on the relationship between metabolic factors such as diabetes mellitus (DM), obesity, and blood lipids and the risk of HCC in patients with CLDs. DM consistently increases the risk of HCC in patients with CLD. When associated with DM, the risk of HCC seems to be highest in HCV and non-alcoholic fatty liver disease (NAFLD), followed by alcoholic liver disease (ALD) and HBV. Obesity may increase the risk of HCC. Among CLDs, the evidence is relatively consistent and clear for ALD, while clear evidence is limited in other CLDs including HBV, HCV, and NAFLD. Total cholesterol, potentially low-density lipoprotein cholesterol and triglyceride, seems to have strong inverse associations with HCC in individuals with CLDs. Despite evidence from observational studies, statins had no effect in preventing HCC in randomized controlled trials. Whether statins have a preventive effect against HCC is unclear. A better understanding and management of metabolic factors may be beneficial to reduce the risk of HCC in patients with CLDs.

摘要

尽管代谢紊乱的患病率不断增加,但代谢因素对慢性肝病(CLD)患者肝细胞癌(HCC)发展的潜在影响尚未得到充分认识。代谢因素要被确定为 CLD 患者(如乙型肝炎病毒(HBV)和丙型肝炎病毒(HCV)感染)的 HCC 危险因素,代谢因素的致癌机制与 CLD 本身之间应该存在强烈的协同相互作用。这篇综述旨在全面总结已发表的关于代谢因素(如糖尿病(DM)、肥胖和血脂)与 CLD 患者 HCC 风险之间关系的研究数据。DM 始终会增加 CLD 患者 HCC 的风险。当与 DM 相关时,HCV 和非酒精性脂肪性肝病(NAFLD)似乎 HCC 的风险最高,其次是酒精性肝病(ALD)和 HBV。肥胖可能会增加 HCC 的风险。在 CLD 中,ALD 的证据相对一致且明确,而在其他 CLD 中,包括 HBV、HCV 和 NAFLD,明确证据有限。在 CLD 患者中,总胆固醇、潜在的低密度脂蛋白胆固醇和甘油三酯似乎与 HCC 呈强负相关。尽管观察性研究有证据,但他汀类药物在随机对照试验中对预防 HCC 没有影响。他汀类药物是否对 HCC 有预防作用尚不清楚。更好地了解和管理代谢因素可能有助于降低 CLD 患者 HCC 的风险。